Related Experiment Video
Updated: Feb 18, 2026
07:34
Author Spotlight: Scaling Microalgal Biotechnology for Enhanced Biomethane Production
Published on: March 22, 2024
3.4K
Equipment review: the molecular adsorbents recirculating system (MARS)
Martin Boyle1, Jelica Kurtovic, David Bihari
1Department of Intensive Care, The Prince of Wales Hospital, Randwick, NSW, Australia. boylem@sesahs.nsw.gov.au <boylem@sesahs.nsw.gov.au>
Critical Care (London, England)
|August 18, 2004
Summary
The molecular adsorbents recirculating system (MARS) may help remove toxins in liver failure. However, current data show poor survival rates, necessitating further research for optimal patient selection and timing.
Area of Science:
- Hepatology
- Artificial Organ Support
Background:
- Acute liver failure (ALF) and acute-on-chronic liver failure (AoCLF) involve multi-organ failure due to albumin-bound toxins.
- Molecular adsorbents recirculating system (MARS) is an artificial liver support system designed to remove these toxins.
Purpose of the Study:
- To evaluate the preliminary clinical efficacy and survival impact of MARS therapy in patients with severe liver dysfunction.
- To identify potential patient subgroups and optimal timing for MARS intervention in ALF and AoCLF.
Main Methods:
- MARS therapy was administered to five patients with severe liver impairment, including three with AoCLF and two with ALF due to sepsis.
- Clinical efficacy and survival rates were assessed retrospectively.
Main Results:
- MARS therapy showed some clinical efficacy in removing toxins.
- The overall survival rate in the studied cohort was low (20%).
Conclusions:
- MARS therapy shows potential for toxin removal in severe liver failure.
- Larger randomized controlled studies are crucial to determine MARS efficacy, optimal timing, and cost-effectiveness in ALF and AoCLF patients.
